FDA Approves Bepirovirsen as First Antisense Oligonucleotide for HBV

The US Food and Drug Administration approved bepirovirsen as the first antisense oligonucleotide therapy targeting viral RNA for chronic hepatitis B, Radio România Cultural reported on October 20, 2026.

Chronic hepatitis B treatment entered a new stage with the regulatory decision, which allows the drug to act directly on viral RNA rather than merely blocking virus replication like conventional antivirals.

The approval rests on results from the Phase III randomized trials B-Well 1 and B-Well 2, which were published in the New England Journal of Medicine.

Hibsago/Bepirovirsen: The First Antisense Oligonucleotide for the Treatment of Hepatitis B — Rahul's Advanced Biology

The findings were discussed during the #raportuldegarda segment on Știința 360 with Dr. Marius Geantă, president of InoMed, the Center for Innovation in Medicine.

Conventional nucleoside and nucleotide analogues suppress viral replication effectively over long periods, but they rarely clear the surface antigen or achieve sustained off-treatment control. Bepirovirsen introduces an antisense oligonucleotide design that binds to hepatitis B virus RNA transcripts, triggering their degradation and limiting the production of subviral particles that exhaust the host immune system.

Data from the B-Well trial program established that this targeted knockdown enables a durable immune-mediated response in nearly one-fifth of treated individuals. The FDA approval announcement formalizes this shift from life-long viral suppression to finite-duration therapy for eligible candidates.

  • Direct RNA Target: The medication destroys the genetic instructions the virus uses to manufacture proteins, going deeper than traditional suppressive drugs.
  • Treatment Holiday Potential: About 19% of trial participants successfully kept the virus under control for nearly half a year after stopping all medication.
  • Finite Regimens: The approach opens a path toward stopping daily antiviral pills for specific patient profiles.

The US decision establishes a regulatory precedent for RNA-targeting agents in chronic viral hepatitis management.

  • U.S. Food and Drug Administration. FDA Press Announcement.
  • New England Journal of Medicine. Phase III B-Well 1 and B-Well 2 Clinical Trials for Bepirovirsen. NEJMoa2515131.
  • raportuldegarda.ro. “Tratamentul hepatitei B cronice intră într-o nouă etapă odată cu aprobarea de către Administrația pentru Alimente și Medicamente din SUA (FDA) a bepirovirsenului (Hibsago), prima terapie bazată pe oligonucleotide antisens autorizată pentru această infecție.” raportuldegarda.ro.
Photo of author

Priya Deshmukh - Senior Editor, Health

Priya Deshmukh Senior Editor, Health Deshmukh is a practicing physician and renowned medical journalist, honored for her investigative reporting on public health. She is dedicated to delivering accurate, evidence-based coverage on health, wellness, and medical innovations.

Gading Marten, Medina Dina, and Gempi Surprise Gisel on Her 36th Birthday

Swedish Church Debates Ending Clergy Right to Refuse Same-Sex Marriages